Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna Inc (NQ: MRNA )

151.56 +2.14 (+1.43%)
Streaming Delayed Price Updated: 2:34 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna Inc

< Previous 1 2 3 4 5 6 7 8 9
...
91 92 Next >
Moderna to Host Fourth Annual Virtual Vaccines Day on April 11, 2023
Via ACCESSWIRE
Why Generation Bio Shares Are Trading Higher Today
Generation Bio (NASDAQ: GBIO) shares are trading higher on Thursday after the company and Moderna (NASDAQ: MRNA) announced a collaboration to develop non-viral genetic medicines. 
Via Benzinga
7 Blue-Chip Stocks Sitting in the Sweet Spot
Although blue-chip stocks carry a reputation for being bulky and not exciting, these large enterprises can really move. 
Via InvestorPlace
Apple Jumps Movie Production Bandwagon, Billionaire Jim Ratcliffe Bids For Manchester United, Elon Musk Seeks Funding For SpaceX From Middle-Eastern Fund: Today's Top Stories
Bloomberg 
Via Benzinga
(MRNA) - Analyzing Moderna's Short Interest
 
Via Benzinga
Moderna, Generation Bio Collaborate To Develop Non-Viral Genetic Medicines
 
Via Benzinga
Check Out What Whales Are Doing With MRNA
 
Via Benzinga
This Is What Whales Are Betting On Moderna
 
Via Benzinga
Moderna and Generation Bio Announce Strategic Collaboration to Develop Non-Viral Genetic Medicines
Via ACCESSWIRE
Moderna and Generation Bio Announce Strategic Collaboration to Develop Non-Viral Genetic Medicines
From Generation Bio Co.; Moderna
Via Globe NewsWire
China's First mRNA Vaccine: Drugmaker CSPC Wins China's Approval For COVID-19 Vaccine
Chinese health authorities approved CSPC Pharmaceuticals Group Ltd's (OTC: CSPCY) messenger RNA (mRNA) COVID-19 vaccine for emergency use authorization. 
Via Benzinga
Additional COVID-19 Booster Shots? Officials Anticipate FDA Authorization Within Few Weeks
The U.S. Food and Drug Administration is reportedly moving toward authorizing a second round of omicron-targeted COVID-19 booster shots for the elderly and other people at high risk. 
Via Benzinga
If You Invested $5,000 in Moderna in 2020, This Is How Much You Would Have Today
Moderna might become a multiproduct company over the next few years. 
Via The Motley Fool
Covid Vaccine Battle Brewing: Moderna's Stephane Bancel Vs. Bernie Sanders
Moderna CEO Stephane Bancel will face a Senate Committee over pricing plans. 
Via Investor's Business Daily
Moderna Wants $130 Per COVID-19 Vaccine Dose, US Health Authorities Warn Of Incurable Deadly Fungal Infection, Elon Musk Wants Interest Rate Cut: Today's Top Stories
Reuters Moderna Wants To Charge About $130 Per COVID-19 Vaccine Dose 
Via Benzinga
Where Did COVID-19 Really Originate? Biden Signs Bill To Declassify Origins Information
 
Via Benzinga
Moderna Wants To Charge About $130 Per COVID-19 Vaccine Dose
From now on, Moderna Inc (NASDAQ: MRNA) expects to charge $130 per dose for its COVID-19 vaccine as purchases move from the government to the private sector. 
Via Benzinga
Credit Suisse's $17B Of AT1 Debt Written Down To Zero, Richard Branson's Virgin Orbit Plans Insolvency, Court Freezes Volkswagen's Russian Assets: Today's Top Stories
Reuters 
Via Benzinga
A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats
A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats 
Via News Direct
Topics Death Economy
Exposures COVID-19 Death Economy
A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats
By Ernest Dela Aglanu, Benzinga 
Via TheNewswire.com
Topics Death Economy
Exposures COVID-19 Death Economy
A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats
With the COVID pandemic still ongoing, having claimed  more than 6.8 million lives from about 758 million cases and crippling the global economy, there are several reasons why drug research and... 
Via Benzinga
2 Undervalued Stocks to Buy Today to Prepare for the Next Bull Market
Both have some headwinds coming up, but their long-term outlook still looks great. 
Via The Motley Fool
Large Vaccine Players Including GSK, Moderna Prepare For Bird Flu Vaccine 'Just In Case'
 
Via Benzinga
12-Stock Portfolio -- 25 Growth Stocks to Buy Now
If I were starting a new growth stock portfolio today, here are the stocks I'd buy. 
Via The Motley Fool
Better RSV Vaccine Stock: Pfizer, GSK, or Moderna?
An approved RSV vaccine could be the next big thing for these companies. 
Via The Motley Fool
Is It Time to Buy the S&P 500's 2 Worst-Performing February Stocks?
Lumen Technologies and Moderna just tumbled, but are these buying opportunities or falling knives? 
Via The Motley Fool
This High-Growth Company Is Expanding. Time to Buy the Stock?
Moderna shares have lost about 15% so far this year. 
Via The Motley Fool
ChatGPT Says These 7 Stocks Could Be the Next Trillion-Dollar Companies
Are you looking for the next trillion-dollar companies? Here are the stocks that ChatGPT thinks will help make you rich in the coming years. 
Via InvestorPlace
2 Top Biotech Stocks to Buy for the Long Haul
These companies have what it takes to grow their revenues -- and their share prices -- over time. 
Via The Motley Fool
3 Vaccine Stocks to Watch for Their Post-Pandemic Moves
The vaccine stocks Pfizer, Moderna, and Novavax all have approved Covid-19 vaccines. They'll soon need new sources of revenue. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
91 92 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.